ブライトライン4：脱分化型脂肪肉腫と呼ばれる癌患者におけるブリギマドリンの忍容性を検証する研究

基本情報

NCT ID

NCT06058793

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

138

治験依頼者名

Boehringer Ingelheim

概要

This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2. The purpose of this study is to find out whether a medicine called brigimadlin (BI 907828) is tolerated by and helps people with DDLPS. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Participants take brigimadlin as a tablet once every 3 weeks. Participants may continue to take brigimadlin as long as they benefit from treatment and can tolerate it. They visit the study site regularly. At the study site, doctors regularly check participants' health and take note of any unwanted effects. The doctors also regularly check tumour size.

対象疾患

介入

依頼者（Sponsor）

実施施設 (10)